






Asiatic Laboratories Limited
Statement of Financial Position (Un-audited)
As at 31 March 2026

Particulars	Notes	Amounts in Taka	
		31 March 2026	30 June 2025
Assets			
Non-Current Assets		7,235,155,363	6,762,866,781
Freehold Property, Plant and Equipment	4.00	6,974,621,277	6,420,114,282
Right of Use Assets	5.00	44,743,932	44,290,651
Intangible Asset	6.00	416,667	791,667
Capital Work-in-Progress	7.00	215,373,486	297,670,181
Current Assets		2,411,539,488	2,102,643,731
Inventories	8.00	748,793,685	636,436,954
Trade and other Receivables	9.00	809,673,445	649,642,970
Advances, Deposits and Prepayments	10.00	830,919,174	798,830,977
Cash and Cash Equivalents	11.00	22,153,184	17,732,830
Total Assets		9,646,694,851	8,865,510,511
Shareholders Equity and Liabilities			
Shareholders Equity		7,032,985,002	6,619,286,431
Share Capital	12.00	1,223,934,550	1,223,934,550
Share Premium	13.00	578,227,731	578,227,731
Revaluation Surplus	14.00	1,617,123,259	1,620,007,837
Retained Earnings	15.00	3,613,699,462	3,197,116,313
Non-Current Liabilities		2,048,432,477	1,731,401,922
Long Term Borrowings	17.00	1,357,802,744	1,040,856,643
Lease Liability (Non-Current Portion)	18.00	37,102,778	31,167,312
Deferred Tax Liability	19.00	653,526,955	659,377,966
Current Liabilities		565,277,372	514,822,159
Short Term Borrowings	20.00	0	63,701,912
Liabilities for Expenses	21.00	29,921,882	22,281,704
Current Tax Payable	22.00	252,336,389	105,312,093
Liability for WPPF	23.00	58,160,498	26,848,791
Long Term Borrowings (Current Portion)	24.00	167,814,932	260,731,439
Lease Liability (Current Portion)	25.00	15,662,297	15,762,592
Trade and other Payables	26.00	13,774,757	6,958,713
Dividend Payable	27.00	27,606,618	13,224,914
Total Shareholders Equity and Liabilities		9,646,694,851	8,865,510,511
Net Asset Value (NAV) per share with Revaluation	35.00	57.46	54.08
Net Asset Value (NAV) per share without Revaluation	35.00	44.25	40.85

The annexed notes form an integral part of these Financial Statements.






 Chief Financial Officer
  Company Secretary
  Director
  Managing Director
  Chairman

Place: Dhaka
Dated: 29 April, 2026

Asiatic Laboratories Limited
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the Period from 1st July 2025 to 31 March 2026

Particulars	Notes	Amounts in Taka			
		Nine Month	Q-3	Nine Month	Q-3
		01 Jul 2025 to 31 March 2026	01 Jan 2026 to 31 March 2026	01 Jul 2024 to 31 March 2025	01 Jan 2025 to 31 March 2025
Net Sales Revenue	27.00	2,288,264,412	788,958,824	1,148,830,961	441,813,882
Less: Cost of Goods Sold	28.00	(1,259,474,040)	(428,480,155)	(652,174,983)	(246,146,251)
Gross Profit		1,028,790,372	360,478,669	496,655,978	195,667,631
Less: Operating Expenses	29.00	(209,508,048)	(72,791,819)	(154,889,032)	(38,884,106)
Profit from Operation		819,282,324	287,686,850	341,766,946	156,783,525
Other Income	30.00	1,202,690	346,570	116,800	(1,076,644)
Financial Expenses	31.00	(157,419,618)	(56,583,041)	(56,545,155)	(31,205,393)
Interest on Lease Liability	32.00	(4,316,869)	(1,445,054)	(828,019)	(274,047)
Profit Before WPPF & Income Tax		658,748,527	230,005,325	284,510,572	124,227,441
Less: Workers' Profit Participation Fund Expenses		(31,311,707)	(10,936,131)	(13,542,561)	(5,966,861)
Profit Before Income Tax		627,436,821	219,069,194	270,968,011	118,260,580
Income Tax Expenses		(141,822,315)	(49,503,918)	(61,343,815)	(26,520,725)
Current Tax	22.00	(147,024,296)	(51,088,084)	(55,215,272)	(27,063,481)
Deferred Tax Income/(Expense)	19.00	5,201,981	1,584,166	(6,128,543)	542,756
Net Profit After Income Tax		485,614,506	169,565,277	209,624,196	91,739,854
Add: Other Comprehensive Income:		649,030	213,349	691,013	227,095
Revaluation surplus during the year		-	-	-	-
Add: Deferred Tax (expenses) /income on Revaluation surplus		-	-	-	-
Adjustment of deferred tax on depreciation for Revaluation Surplus		649,030	213,349	691,013	227,095
Total Comprehensive Income for the year		486,263,536	169,778,625	210,315,209	91,966,949
Earnings Per Share (EPS)	34.00	3.97	1.39	1.71	0.75
Number of share considered for calculating EPS		122,393,455	122,393,455	122,393,455	122,393,455

The annexed notes form an integral part of these Financial Statements.

Chief Financial Officer Company Secretary Director Managing Director Chairman

Place: Dhaka
Dated: 29 April, 2026

Asiatic Laboratories Limited
Statement of Changes in Equity (Un-audited)
For the Period from 01 July 2025 to 31 March 2026

(Amount in Taka)


Particulars	Ordinary Share Capital	Share Premium	Revaluation Surplus	Retained Earnings	Total
Balance as at July 01, 2025	1,223,934,550	578,227,731	1,620,007,837	3,197,116,313	6,619,286,431
Adjustment of depreciation for			(2,884,578)	2,884,578	-
Declared of Cash Dividend @ 10% excluding Director				(72,564,965)	(72,564,965)
Adjustment of deferred tax on depreciation for Revaluation Surplus				649,030	649,030
Net profit for the year transferred from Statement of Profit or Loss & Other Comprehensive Income				485,614,506	485,614,506
Balance as at 31 March 2026	1,223,934,550	578,227,731	1,617,123,259	3,613,699,462	7,032,985,002

Asiatic Laboratories Limited
Statement of Changes in Equity (Un-audited) 9 Month
For the period ended 31 March, 2025


(Amount in Taka)


Particulars	Ordinary Share Capital	Share Premium	Revaluation Surplus	Retained Earnings	Total
Balance as at July 1, 2024	1,223,934,550	578,227,731	1,624,138,128	3,009,259,939	6,435,560,348
Adjustment of depreciation for Revaluation Surplus			(3,071,168)	3,071,168	-
Issuance of Cash Dividend @ 10% excluding Director				(72,564,965)	(72,564,965)
Adjustment of deferred tax on depreciation for Revaluation Surplus (22.50%)				691,013	691,013
Net profit for the year transferred from Statement of Profit or Loss & Other Comprehensive Income				209,624,196	209,624,196
Balance as at 31 March 2025	1,223,934,550	578,227,731	1,621,066,960	3,150,081,350	6,573,310,592


Chief Financial Officer


Company Secretary


Director


Managing Director







Chairman

Place: Dhaka

Dated: 29 April, 2026

Asiatic Laboratories Limited
Statement of Cash Flows (Un-audited)
For the Period from 1st July 2025 to 31 March 2026

Particulars	Note	Amounts in Taka	
		01 Jul 2025 to 31 March 2026	01 Jul 2024 to 31 March 2025
A. Cash Flows from Operating Activities			
Received from Customers	38.06	2,128,233,937	985,375,670
Paid to Suppliers	38.07	(1,175,825,320)	(580,279,495)
Paid to Employee	38.08	(159,831,749)	(125,741,986)
Paid for Manufacturing & Operating Expenses	38.09	(69,368,539)	(57,231,353)
Received from Other Sources		1,202,690	116,800
Tax Paid		(23,410,573)	(10,839,132)
Net Cash Generated From Operating Activities		701,000,446	211,400,503
B. Cash Flows from Investing Activities			
Acquisition of Freehold Property, Plant and Equipment	38.10	-	(69,960,618)
Advance for building construction & plant		-	(110,000,000)
Acquisition of Intangible Assets	38.12		
Paid for Capital Work In Progress	38.13	(632,489,395)	(770,054,990)
Net Cash Used to Investing Activities		(632,489,395)	(950,015,608)
C. Cash Flows from Financing Activities			
Long Term Loan Payment	38.14	224,029,594	699,529,909
Short Term Loan Payment		(63,701,912)	25,588,065
Lease Liability Payment during the Year	38.15	(4,498,631)	(11,551,083)
IPO Expenses paid		-	-
Paid for Cash Divident		(58,183,262)	(61,571,900)
Interest on Lease Liability		(4,316,869)	(828,019)
Paid for Financial Cost		(157,419,618)	(56,545,155)
Net Cash Used in Financing Activities		(64,090,697)	594,621,816
D. Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)		4,420,354	(143,993,288)
E. Cash and Cash Equivalents at the Beginning of the period		17,732,830	159,416,985
F. Cash and Cash Equivalents at the end of the Period (D+E)		22,153,184	15,423,697
Net Operating Cash Flows Per Share (NOCFPS)	36.00	5.73	1.73

 Chief Financial Officer
 Company Secretary
 Director
 Managing Director
 Chairman

Place: Dhaka
Dated: 29 April, 2026